Status
Conditions
Treatments
About
The biopsychosocial integrated intervention program is an effective model for improving holistic health in elderly patients with geriatric disease-related secondary depression, significantly alleviating depressive symptoms, enhancing mental health, and elevating quality of life.
Full description
To investigate the effects of a tripartite biopsychosocial intervention program on mental health and quality of life in elderly patients with depression secondary to geriatric diseases. A cluster randomized controlled trial was conducted with 166 elderly patients with secondary depression in our hospital between January 2022 and January 2025. Wards were randomized into an intervention group (n = 83) and a control group (n = 83) using SPSS-generated random sequences. The intervention group received a biopsychosocial integrated program, while the control group received standard psychiatric care. Outcomes were assessed at baseline, 1, 2, and 3 months post-intervention using the 17-item Hamilton Rating Scale for Depression (HAMD-17), mental health indicators [Profile of Mood States (POMS), Five Facet Mindfulness Questionnaire (FFMQ), and Mental Health Continuum-Short Form (MHC-SF)], and the Generic Quality of Life Inventory-74 (GQOLI-74). Patient satisfaction was evaluated post-intervention.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis of depression secondary to geriatric disease (ICD-10 criteria)
Age ≥60 years
Baseline HAMD-17 score ≥14 (mild depression or worse)
Mini-Mental State Examination (MMSE) score ≥24 (no significant cognitive impairment)
Willing and able to provide informed consent (patient or guardian)
Stable on current medications for ≥4 weeks prior to enrollment
Exclusion criteria
Primary psychiatric disorders:
Schizophrenia or bipolar disorder
Severe personality disorders
Active suicidal ideation or psychotic symptoms
Recent treatment history:
Antipsychotic medication within 3 months
Electroconvulsive therapy within 6 months
Participation in other interventional trials
Neurological conditions:
Alzheimer's disease or vascular dementia
Parkinson's disease with cognitive impairment
Brain tumors or traumatic brain injury
Medical comorbidities:
Terminal illness with life expectancy <6 months
Uncontrolled cardiovascular disease
Severe hepatic/renal insufficiency (GFR <30 mL/min)
Substance abuse disorders (alcohol or drugs within past year)
Primary purpose
Allocation
Interventional model
Masking
166 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal